SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending following a proposed business combination with Applied Digital's cloud computing unit to form ChronoScale, an AI GPU compute platform. This strategic pivot into the high-demand AI infrastructure sector has fueled intense community discussion, with many anticipating significant growth given the company's low float. However, some investors are raising concerns about potential shareholder dilution and the deal's non-binding status.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire is gaining significant attention following a new eight-figure contract to provide spacecraft docking systems for a European space capsule, igniting discussions among investors. The community is actively highlighting the company's perceived undervaluation, short squeeze potential, and strategic position within the burgeoning space and defense sectors. Many anticipate substantial growth from Redwire's diverse portfolio, including space infrastructure, microgravity development, and advanced drone technologies, with some aggressively buying dips in expectation of future catalysts and sector-wide expansion.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is a focal point of market discussion, driven by anticipation surrounding its AI-powered Athena platform and potential announcements at the upcoming CES 2026. The community largely views the stock as significantly undervalued, pointing to its strong fundamentals, leadership in AI-driven marketing technology, and the potential for a substantial re-rating in the near term. Many are actively discussing recent dips as prime buying opportunities for long-term growth.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera is actively discussed following news of Georgia's Ministry of Justice integrating the network for its national public registry with potential for real estate tokenization, and Archax executing tokenized ETF transactions on the platform. This substantial real-world adoption reinforces its perception as an enterprise infrastructure play, prompting many in the community to accumulate amidst current market conditions, even as some express deep skepticism about its immediate price trajectory.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending amidst intense investor frustration over prolonged management silence regarding potential partnerships for its critical combined flu/COVID vaccine. Community discussion is dominated by calls for CEO John Jacobs' removal and speculation that the quiet signals imminent major deals or a potential buyout, especially given the company's protein-based platform and activist pressure from Shah Capital.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is actively trending amid significant buzz around its AI initiatives, particularly its Kunlunxin chip division reportedly replacing Nvidia hardware for Deepseek's inference and exploring a Hong Kong IPO. The community is eagerly discussing the considerable undervaluation of Baidu's Apollo Go autonomous driving unit compared to global peers, fueled by a recent major analyst upgrade highlighting strong growth potential in AI and cloud services.

NioCorp Developments Ltd. engages in the evaluation, acquisition, exploration, and development of mineral deposits. It focuses on a super alloy materials project in Nebraska for producing niobium, scandium, and titanium. The company was founded on February 27, 1987, and is headquartered in Centennial, CO.

NioCorp Developments Ltd

NioCorp is trending following its announcement to begin mine portal construction in Q1 2026 for the Elk Creek Critical Minerals Project, solidifying its position as a strategic US source for niobium, scandium, titanium, and rare earths. This comes amidst significant government interest, including a Pentagon-backed partnership with Lockheed Martin, though community sentiment remains mixed due to ongoing project timeline discussions and anticipation for updated feasibility studies and financing. The company's progress is critical for establishing a robust domestic supply chain, reducing reliance on foreign sources for essential materials.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind is trending due to recent regulatory progress for its FUROSCIX ReadyFlow autoinjector and ongoing discussions about the Afrezza launch in India. While optimism surrounds the autoinjector's potential to significantly impact the edema market and the continued success of its partnership with United Therapeutics, community sentiment is divided on Afrezza's international prospects, and the company's leadership remains a point of contention among investors.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to upcoming near-term FDA decisions for multiple pipeline assets, notably a motion sickness treatment and a jet lag disorder re-review, with a PDUFA target action date upcoming for Tradipitant. Investors are actively discussing the significant potential of Tradipitant to address GLP-1 induced nausea and vomiting, believing current valuations are significantly undervalued given the breadth of upcoming catalysts and the company's recent collaborative framework established with the FDA.

FTAI Aviation Ltd. focuses on owning, leasing, and servicing commercial jet engines, with a primary focus on CFM56 and V2500 engines. Its portfolio of products, including the Module Factory and a joint venture to manufacture engine PMA components, enables cost savings and flexibility for its airline, lessor, and MRO customer base. The company operates through two segments: Aviation Leasing and Aerospace Products. The Aviation Leasing segment owns and manages aviation assets, including aircraft and engines, which it leases and sells to customers. The Aerospace Products segment develops, manufactures, repairs/refurbishes, and sells aircraft engines and aftermarket components for the CFM56-7B, CFM56-5B, and V2500 engines through its maintenance facilities, equity method investments, and exclusivity arrangements. FTAI Aviation is headquartered in New York, NY.

FTAI Aviation Ltd - Ordinary Shares - Class A

FTAI Aviation Ltd

FTAI Aviation is trending as its audit committee declared previous short seller allegations "without merit," coinciding with strong earnings results and an increased dividend. The community is actively discussing the company's strategic capital initiatives and its role in converting aircraft engines for AI data center energy supply, with many anticipating continued growth and a potential short squeeze after recent analyst upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Hold" from the eight research firms that are presently covering the company, MarketBeat.com...

129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...

Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?

CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.

Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Squarepoint Ops LLC cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 67.0% during the second quarter, according to the company in its most recent...

Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The...

CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays

Barclays upgraded Amphastar Pharmaceuticals to a "hold" rating in a research report on Monday...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays

Barclays initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday. They set an "equal weight" rating and a $30.00 target price for the company...

Marshall Wace LLP Sells 183,037 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Marshall Wace LLP decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the...

Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 188.8% during the second quarter, according to the company in its most recent 13F...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

AMPH
Amphastar Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMPH News

AMPHAmphastar Pharmaceuticals Inc